Mantle, a blockchain platform backed by crypto exchange Bybit, is expanding to the fast-growing real-world asset (RWA) sector with a new tokenization service designed to bring traditional finance on ...

Named after the 19th-century scientist who first described abnormal masses in the lymph nodes, Hodgkin lymphoma is a cancer of the lymphatic system. Around 10% of lymphoma diagnoses are categorized as ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Please provide your email address to receive an email when new articles are posted on . In this video, Tycel Phillips, MD, expands on the shifting and complex treatment landscape for mantle cell ...

HOUSTON -- Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, ...

Patients with high-risk treatment-refractory mantle cell lymphoma (MCL) show significant survival benefits with treatment with mosunetuzumab combined with polatuzumab vedotin (mosun-pola), new ...

Sonrotoclax showed significant efficacy in relapsed or refractory mantle cell lymphoma, achieving a high overall response rate and manageable safety profile. The drug offers advantages over venetoclax ...

BeOne Medicines Ltd. (NASDAQ:ONC) (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with ...

A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma (MCL). The single-arm ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417 ...

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet need BeOne to submit data to global regulatory ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...